CTLA4 and cancer: Because CTLA4 acts is a different stage of the cancer immunity cycle compared to PD1, inhibiting both checkpoints is synergistic, with anti-PD1/anti-CTLA4 combination therapy yielding improved clinical benefit relative to anti-PD1 monotherapy [5].